Trial Profile

Phase IIb Open-label Trial of SUBA-Itraconazole in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Itraconazole (Primary)
Indications Basal cell cancer; Carcinoma
Focus Registrational; Therapeutic Use
Acronyms SCORING
Sponsors INHIBITOR Therapeutics

Most Recent Events

19 Dec 2023 According to the Inhibitor Therapeutics media release, Scientific Advisory Board tasked with critical review of Phase 2b trial results to assess clinical usefulness prior to submission of New Drug Application to FDA
13 Dec 2023 Results presented in the Inhibitor Therapeutics Media Release
03 Aug 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com